Funding for this research was provided by:
National Institutes of Health (R01 NS094067)
Swedish State support for Clinical Research (ALFGBG-717531, ALFGBG-715986, and ALFGBG-720931)
Received: 26 September 2018
Accepted: 9 January 2019
First Online: 24 January 2019
Ethics approval and consent to participate
: The study was approved by the Regional Ethics Review Board in Gothenburg, Sweden (Ö588-01) and was performed in accordance with the Helsinki Declaration. All participants gave their informed consent.
: Not applicable
: HZ has served on scientific advisory boards for Eli Lilly, Roche Diagnostics, and Wave; he has received travel grants from Teva; and he is also a co-founder of Brain Biomarker Solutions in Gothenburg AB, a venture-based platform company at the University of Gothenburg.KB has served as a consultant or on advisory boards for Alzheon, BioArctic, Biogen, Eli Lilly, Fujirebio Europe, IBL International, Merck, Novartis, Pfizer, and Roche Diagnostics. He is also a co-founder of Brain Biomarker Solutions in Gothenburg AB, a venture-based platform company at the University of Gothenburg. The other authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.